Cholecystokinin-8 vs Noopept
Head-to-head comparison of Cholecystokinin-8 (Cholecystokinin (sulfated C-terminal octapeptide, CCK-8)) and Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Cholecystokinin-8 | Noopept |
|---|---|---|
| Category | Endocrine Peptides | Cognitive Enhancement |
| Full Name | Cholecystokinin (sulfated C-terminal octapeptide, CCK-8) | N-phenylacetyl-L-prolylglycine ethyl ester |
| Molecular Weight | 1143.2 Da | 318.37 Da |
| Half-Life | 1-2 min | 20-30 minutes |
| Amino Acids | DY(SO3H)MGWMDF-NH2 | N/A |
| Typical Dose | physiologic low-picomolar-nanomolar range|research-dependent | 10-30 mg/day |
| Route | endogenous secretion|research IV/SC | Oral |
| Purity | ≥98% | ≥98% |
| Studies Count | 97 | 60 |
| Research Status | Endogenous | Clinical |
Cholecystokinin-8 Benefits
- ✓gallbladder contraction
- ✓pancreatic enzyme release
- ✓satiety signaling
Noopept Benefits
- ✓memory recall
- ✓learning efficiency
- ✓attention support
- ✓neurotrophic signaling
Cholecystokinin-8 Dosing
physiologic secretion|research-dependent
Noopept Dosing
oral research use|10-30 mg per day in human studies|divided or single daily dosing
Cholecystokinin-8 Side Effects
- ⚠abdominal cramping
- ⚠nausea
- ⚠biliary contraction
Noopept Side Effects
- ⚠headache
- ⚠irritability
- ⚠sleep disturbance
Research Overview
Cholecystokinin-8
CCK-8 is a canonical gut hormone fragment with extensive documentation in digestive physiology and appetite control. Sulfation of the tyrosine residue is important for high-affinity receptor activity.
Noopept
Noopept has been reported to increase NGF/BDNF-related signaling and improve performance in tasks involving learning and recall. Evidence includes preclinical studies and small human studies, but the overall literature is still modest compared with mainstream cognitive drugs.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.